BJC Reports最新文献

{"title":"Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre","authors":"Nicole L. Brown, Susan Pritchard, Elaine F. Harkness, Yit Lim, Ashu Gandhi, Dafydd Gareth Evans, Anthony Howell, Sacha J. Howell","doi":"10.1038/s44276-024-00113-2","DOIUrl":"10.1038/s44276-024-00113-2","url":null,"abstract":"Atypical ductal hyperplasia (ADH) and lobular neoplasia (LN) increase subsequent breast cancer (BC) risk. However, optimal surveillance and risk reduction regimes remain uncertain. We report management and outcomes of women with ADH and LN to provide data on potential screening/prevention strategies. Women diagnosed with screen detected ADH and/or LN between 2010-2018 at our institution were identified and demographic data, MDT decisions and BC diagnoses extracted from electronic patient records in 2019 and 2023. Of 107 women, 74 were discharged to the NHS Breast Screening Programme and 33 were offered enhanced screening (ES). The proportion offered ES increased significantly over time (p = 0.037). 15/105 (14.3%) developed BC (median follow-up 117 months), 9 screen-detected and 6 symptomatic, with 3 interval cancers diagnosed 12–25 months following their last screen. 3/15 were lymph node positive and 13/14 invasive cancers were estrogen receptor (ER) positive. BC incidence rate was 1499.6/100,000 women/year (SIR = 4.7), lower in the first 5 years of follow-up compared with post 5 years. In women with ADH/LN most BCs occur beyond 5 years. ES regimens should therefore extend to at least 10 years and be at least biennial. Preventative therapy should be considered given the high BC SIR and ER positivity of subsequent tumours.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00113-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial","authors":"Helena Taflin, Elisabeth Odin, Göran Carlsson, Bengt Gustavsson, Oskar Hemmingsson, Yvonne Wettergren, Krzysztof Urbanowicz, Jacek Turyn, Ryszard T. Smolenski, Godefridus J. Peters","doi":"10.1038/s44276-024-00111-4","DOIUrl":"10.1038/s44276-024-00111-4","url":null,"abstract":"5-Fluorouracil (5-FU) is a cornerstone in treatment of colorectal cancer (CRC) and is usually combined with leucovorin (LV) to enhance the antitumour effect by increase thymidylate synthase (TS) inhibition, the key target enzyme for 5-FU. Arfolitixorin (Arfo) is an active form of the reduced folate, [6 R]-5,10-methylenetetrahydrofolate ([6 R]-MeTHF and in contrast to LV, does not need to be metabolized. The Modelle-001 was designed to explore whether a single intravenous bolus injection of Arfo as compared to LV, together with 5-FU increases the inhibition of TS, levels of folate concentrations and polyglutamylation in CRC liver metastases (CRLM) and liver parenchyma. Thirty patients with CRLM received either LV (60 mg/m2) or Arfo (30 mg/m2 or 120 mg/m2) in combination with 5-FU preoperatively. Levels of folates and and TS inhibition were measured. Significantly higher MeTHF levels and higher TS inhibition were measured in the Arfo groups compared to LV60, and there was a difference in folate poly-glutamylation between the groups. The Modelle-001 Trial demonstrated significantly higher levels of MeTHF in metastases following Arfo compared to LV. This resulted in a greater increase TS inhibition in metastases although not statistically significant.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00111-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142672807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA-seq analysis of cancer-endothelial cell interactions in primary tumor and peritoneal metastasis from a single patient with colorectal cancer","authors":"Yuri Sakimoto, Kohei Kumegawa, Shimpei Matsui, Tomohiro Yamaguchi, Toshiki Mukai, Koji Okabayashi, Seiichi Mori, Yuko Kitagawa, Takashi Akiyoshi, Reo Maruyama","doi":"10.1038/s44276-024-00112-3","DOIUrl":"10.1038/s44276-024-00112-3","url":null,"abstract":"Peritoneal metastasis, a major complication of colorectal cancer (CRC), often leads to poor quality of life and unfavorable outcomes. Despite numerous studies characterizing its biological features in CRC, intratumor heterogeneity and interactions between cancer cells and tumor microenvironment cells remain poorly understood. To explore these aspects, we performed single-cell transcriptome analysis of matched primary tumor and peritoneal metastasis samples from a treatment-naïve patient. Our analysis revealed enrichment of “tip” endothelial cells in the primary tumor, driving angiogenic sprouting, whereas these cells were absent in peritoneal metastases. Moreover, cancer cells in peritoneal metastasis displayed a distinct expression signature associated with epithelial–mesenchymal transition and tumor invasiveness. Analysis of cell–cell communication between endothelial and tumor cells revealed decreased VEGF signaling and increased CXCL–ACKR1 interactions in peritoneal metastasis. Although limited by its N-of-1 design and requiring further validation, our study provides preliminary observations suggesting that alterations in cancer-endothelial cell interactions could reduce dependence on VEGF signaling and influence immune cell infiltration in CRC peritoneal metastasis.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00112-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer","authors":"Shristi Bhattarai, Manali Rupji, Hsueh-ping Chao, Qi Xu, Geetanjali Saini, Padmashree Rida, Mohammed A. Aleskandarany, Andrew R. Green, Ian O. Ellis, Emiel A. Janssen, Kristin Jonsdottir, Emad Rakha, Jeanne Kowalski, Ritu Aneja","doi":"10.1038/s44276-024-00097-z","DOIUrl":"10.1038/s44276-024-00097-z","url":null,"abstract":"Ki67 index (KI) and mitotic index (MI) are proliferation markers with established prognostic value in breast carcinomas. While KI is evaluated immunohistochemically and reported as a percentage, MI is determined visually and reflects total mitotic cells in 10 high-power fields. Our objective was to integrate KI and MI into a novel metric; the cell cycle traverse rate (CCTR). Given the lack of prognostic and predictive biomarkers in TNBC, we sought to assess the potential of CCTR as a risk-stratification tool for chemotherapy-treated TNBC patients from two independent cohorts: the Nottingham group (n = 124) and the Norway group (n = 71). We evaluated the ability of CCTR to predict survival after adjuvant chemotherapy for TNBC patients (n = 195) in two independent cohorts. Using immunohistochemistry and RNA sequencing, we determined the differences in immunohistochemical biomarkers, gene ontologies, molecular pathways and immune cell fractions based on CCTR. TNBC shows a significantly lower median CCTR compared to luminal A (p < 0.01), luminal B (p < 0.01), and HER2+ samples (p < 0.01). CCTR outperformed both KI and MI in effectively risk-stratifying TNBC patients suggesting that combining KI and MI into a single metric, namely CCTR, could serve as a superior prognostic marker for Breast Cancer Specific Survival (BCSS) (p = 0.041). CCTR-high group exhibited enriched expression of various oncogenic signatures, including angiogenesis, epithelial-to-mesenchymal transition (EMT), Hedgehog signaling, hypoxia, Notch signaling, PI3K-AKT-mTOR signaling, TGFβ signaling, p53 signaling, and TNFα signaling via NFκB. These findings suggest the potential involvement of these pathways in the aggressiveness and clinical outcomes of TNBC patients. Collectively, these findings suggest that CCTR offers superior predictive information compared to KI and MI alone with respect to long-term outcomes from adjuvant chemotherapy in patients with TNBC that may guide treatment decision making.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00097-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis","authors":"Rehena Sultana, Sylvia Chen, Elaine Hsuen Lim, Rebecca Dent, Balram Chowbay","doi":"10.1038/s44276-024-00106-1","DOIUrl":"10.1038/s44276-024-00106-1","url":null,"abstract":"Sacituzumab govitecan (SG) is a promising Trop-2-targeted antibody-drug conjugate (ADC) approved for the treatment of metastatic triple-negative breast cancer (TNBC). Early phase clinical trials have demonstrated good clinical activity and safety profile of SG in various tumor types, albeit with differing response rates and durations. The aim of this systematic review and meta-analysis was to evaluate the clinical efficacy and toxicity of SG and the influence of UGT1A1*28 genotype in clinical trials involving solid tumors. A systematic review of the literature from publicly available databases was performed on February 15, 2024 whereby studies published till 15 February 2024 were retrieved according to PRISMA guidelines [PROSPERO #CRD42022359943]. Data extracted included tumor type, sample size, demographic information, SG dose, UGT1A1*28 status, toxicity events, duration of follow-up, response, and survival outcomes. Risks of bias analysis was refereed using the Joanna Briggs Institute quality assessment tool for the cohort and RCT studies using 11 and 13 parameters, respectively. Statistical analysis was performed using the DerSimonian and Laird inverse variance methods. Heterogeneity was assessed using the I2 statistic and Χ2 tests. P value < 0.05 was considered as statistical significance. Eleven eligible clinical trials comprised of 1578 patients harboring various tumor types including TNBC, lung, genitourinary and gastrointestinal malignancies were included in the systematic review and meta-analysis. Pooled incidences of severe adverse events were minimal at <10%, with the exception of grade 3–4 neutropenia at 37.4%. The median PFS and OS across all studies were 4.9 (95%CI: 4.0-5.8) months and 9.6 (95%CI: 7.6-11.6) months, respectively. Objective response rate across all studies evaluated was 17.1% (95%CI: 12.0–22.1). Our systematic review and meta-analysis confirmed that SG confers good clinical activity in certain solid tumor types and was tolerable with minimal adverse events. The potential utility of UGT1A1*28 genotyping in predicting clinical response and outcomes could not be determined due to the limited number of studies with available UGT1A1 genotype data.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00106-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of risk prediction tools for primary cutaneous melanoma outcomes and validation of sentinel lymph node positivity prediction in a UK tertiary cohort","authors":"R. N. Manton, A. Roshan","doi":"10.1038/s44276-024-00110-5","DOIUrl":"10.1038/s44276-024-00110-5","url":null,"abstract":"It is difficult for clinicians to make predictions for cancer progression or outcomes based on AJCC staging for individual patients. Models individualising risk prediction for clinical outcomes are developed using patient level data, advanced statistical techniques, and artificial intelligence. A systematic search identified cutaneous melanoma prognostic prediction tools published between January 1985–March 2023. Population comparisons of key clinico-pathological variables, external prediction of receiver operating characteristics and calibration analysis are applied to an unselected group of patients undergoing sentinel lymph node biopsy in a UK University hospital setting (n = 1564). Twenty-nine models were identified which predicted survival, disease recurrence or sentinel lymph node positivity (Internal validation n = 19 and external validation n = 14). 3 out of 7 tools for sentinel node positivity were contemporaneous with available characteristics for external validation. External validation of models by Lo et al. Friedman et al. & Bertolli et al. highlighted good discriminative performance (AUC 68.1% (64.5–71.8%), 77.1% (66.8–85.7%) & 68.6% (63.3–74.1%) respectively) but were sub-optimally calibrated for the UK patient cohort (Calibration intercept & slope Friedman: −4.01 & 32.92, Lo: −1.17 & 0.44, Bertolli: −2.75 & 4.88). This work highlights the complexity of predictive modelling and the rigorous validation process necessary to ensure accurate predictions. Our search highlights a tendency to focus on discriminative performance over calibration, and the possibility for inconsistent predictions when tools are applied to populations with differing characteristics.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00110-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study","authors":"Chantal F. Stockem, Sarah M. H. Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Dimitra R. Bakaloudi, Rafee Talukder, Belen Caramelo, Rafael Morales-Barrera, Astrid De Meulenaere, Alessandro Rametta, Andrea Bottelli, Felix Lefort, Patrizia Giannatempo, Christof Vulsteke, Joan Carles, Ignacio Duran, Petros Grivas, Alfonso Gómez de Liaño, Debbie G. J. Robbrecht, Begoña P. Valderrama, Vincent van der Noort, Michiel S. van der Heijden","doi":"10.1038/s44276-024-00104-3","DOIUrl":"10.1038/s44276-024-00104-3","url":null,"abstract":"Anti-PD-(L)1 agent are approved as first- and second-line treatment options in advanced urothelial cancer (UC), but information about long-term survival is scarce. There is a need for prognostic factors, as these may help in the decision-making concerning anti-PD-(L)1 in patients with UC. Here, we examined long-term survival following anti-PD-(L)1 in advanced UC and assessed clinical factors for their correlation with survival. We collected data from patients with advanced UC treated with anti-PD-(L)1 between 2013 and 2023. Overall- and progression-free survival (OS, PFS) were determined using the Kaplan-Meier method. Independent variables were analysed by uni- and multivariate Cox regression for their association with OS and PFS. Survival analyses included 552 patients. Patient characteristics in our cohort were consistent with those of a typical advanced UC population. After median follow-up of 49 months, five-year OS and PFS rates were 16.0% and 6.9% respectively. The absence of visceral and/or bone metastases and elevated C-reactive protein level, gamma-glutamyltransferase level and neutrophil-to-lymphocyte ratio were identified as favourable prognostic factors for OS. A selected subset of patients with advanced UC may experience long-term clinical benefit from anti-PD-(L)1 treatment. We identified prognostic factors that might be used for risk assessment and clinical trial stratification.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00104-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using the Candidacy Framework to understand individual, interpersonal, and system level factors driving inequities in women with breast cancer: a cross-sectional study","authors":"Mar Estupiñán Fdez. de Mesa, Afrodita Marcu, Emma Ream, Katriina L. Whitaker","doi":"10.1038/s44276-024-00103-4","DOIUrl":"10.1038/s44276-024-00103-4","url":null,"abstract":"Persistent inequities in breast cancer outcomes exist. Understanding women’s experiences along the care pathway is the first step to finding solutions to tackle these inequities. Secondary data analysis of the 2017/2018 English National Cancer Patient Experience Survey (n = 25,408) using logistic regression to explore inequities in care experience by sociodemographic factors (age, ethnicity, socioeconomic position, sexual orientation) across 59 survey questions. We used the Candidacy Framework to interpret and organise our findings. Compared to older (65–74) and White British women, young (35-44, OR = 0.55 [0.44, 0.69]), Asian (OR = 0.52 [0.41, 0.67]), Black (OR = 0.67 [0.46, 0.97]) and White Other (OR = 0.63 [0.49, 0.81]) women were more likely to rate their overall care experience less positively, respectively. Similar findings were observed along all domains of the cancer pathway. Through a candidacy lens, we identified multilevel factors related to this variation including prolonged help-seeking behaviours (individual), poor patient-provider communication (interpersonal), and variation in access to healthcare professionals and resources (system level). Multilevel factors influence inequities in the experience of care along the breast cancer pathway for young women and women from minoritised groups. Interventions are necessary to ensure cancer care systems are responsive to women’s health needs and provide equity of care to all patients.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00103-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer","authors":"Andreas Bjerrum, Andreas Frederik Henriksen, Ann Søegaard Knoop, Tobias Berg, Ida Elisabeth Viller Tuxen, Ulrik Lassen, Tonny Studsgaard Petersen","doi":"10.1038/s44276-024-00108-z","DOIUrl":"10.1038/s44276-024-00108-z","url":null,"abstract":"Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor positive/HER2-negative metastatic breast cancer is CDK4/6 inhibitor plus endocrine therapy. Understanding the impact of CDK4/6 inhibitor dose reduction, which occurs in about half of the patients, is important. This real-world cohort study is based on electronic health records from Capital Region of Denmark. All women with metastatic breast cancer initiating first-line treatment with CDK4/6 inhibitor between May 2017 and October 2022 were included. A total of 546 patients were eligible for inclusion in the 12-week landmark analysis and 192 (35%) experienced dose reduction. These patients were older, had worse ECOG PS, more received prior adjuvant endocrine treatment, and more received fulvestrant as the endocrine backbone. Dose reduction was associated with reduced overall survival (39.9 vs. 54.3 months) and shorter treatment duration (18.0 vs. 26.9 months). Adjusted hazard ratio for death was 1.38 (95% CI: 1.01–1.89). Dose reduction of CDK4/6 inhibitors within the first 12 weeks of treatment was associated with significantly higher mortality and shorter treatment duration. These findings contrast with previous analyses showing no effect of dose reduction, likely due to considering immortal time bias in this study.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00108-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loss of vimentin expression in preoperative biopsies independently predicts poor prognosis, lymph node metastasis and recurrence in endometrial cancer","authors":"Marta E. Hjelmeland, Hilde E. Lien, Hege F. Berg, Kathrine Woie, Henrica M. J. Werner, Frédéric Amant, Ingfrid S. Haldorsen, Jone Trovik, Camilla Krakstad","doi":"10.1038/s44276-024-00105-2","DOIUrl":"10.1038/s44276-024-00105-2","url":null,"abstract":"Precise preoperative risk classification of endometrial cancer is crucial for treatment decisions. Existing clinical markers often fail to accurately predict lymph node metastasis and recurrence risk. Loss of vimentin expression has emerged as a potential marker for predicting recurrence in low-risk endometrial cancer patients. We assessed whether vimentin expression in preoperative biopsies predicts poor prognosis and lymph node metastasis in a large multicentre cohort. Vimentin expression was evaluated using immunohistochemistry in 1483 patients diagnosed with endometrial cancer across 14 hospitals in Europe. Expression levels of vimentin were analyzed in conjunction with clinical characteristics for predicting disease-specific survival and lymph node metastases. Vimentin loss was significantly associated with aggressive disease and poor survival. Adjusted for clinicopathological variables, vimentin remained independently prognostic with a hazard ratio (HR) of 1.68 (95% CI 1.16–2.42, P = 0.006). Vimentin expression remained independently prognostic in endometrioid endometrial cancer- and FIGO staged 1 patient. Interestingly, vimentin loss independently predicted lymph node metastases, with an HR of 1.83 (95% CI 1.13–2.95, P = 0.014). Loss of vimentin in preoperative biopsies serves as an independent predictor of poor prognosis and lymph node metastases. Incorporating vimentin as a clinical marker can improve risk stratification and treatment decisions.","PeriodicalId":135222,"journal":{"name":"BJC Reports","volume":" ","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s44276-024-00105-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}